Introduction
============

Prostate cancer is the most common cancer in older men in the UK, the US, and western Europe.[@b1-ce-8-001] Despite its high incidence, it will frequently respond to treatment when widespread, and may be cured when localized.[@b2-ce-8-001] Radical prostatectomy and radiation therapy appear to yield similar survival rates with as many as 10 years of follow-up.[@b2-ce-8-001]

The optimal external-beam radiation therapy (EBRT) schedule for the curative treatment of localized prostate carcinoma is still uncertain.[@b3-ce-8-001]--[@b6-ce-8-001] The National Comprehensive Cancer Network recommends that a three-dimensional technique or intensity-modulated radiation therapy (IMRT) should be used to treat prostate cancer. Doses of 75.6--79.2 Gy in conventional fractions to the prostate are appropriate for patients with low-risk cancers. For patients with intermediate-risk or high-risk disease, doses up to 81.0 Gy provide improved disease control as assessed by prostate-specific antigen (PSA).[@b7-ce-8-001] Dose escalation and neoadjuvant androgen deprivation improve disease control, but the former increases side effects affecting the bowel.[@b8-ce-8-001]

In ideal circumstances, the fractionation schedule of radiotherapy should match the fractionation sensitivity of the tumor relative to nearby normal tissues. A number of recent publications have suggested that the alpha-beta (α/β) ratio for the prostate is low, in the range of 1--3 Gy. If the α/β ratio is truly low, then hypofractionated schedules using fewer and larger fractions should improve the therapeutic results.[@b9-ce-8-001] Hypofractionating external beam radiotherapy (HEBRT) with fractions ≥ 2.5 Gy per day can theoretically maintain high bioequivalent tumor doses without increasing acute and late toxicities, while decreasing treatment visits (which is convenient for patients), increasing treatment capacity, and reducing cost.[@b10-ce-8-001]

Nonrandomized studies from the UK, Australia, Canada, the US, and Uruguay have reported that use of shorter radiation fractionation schedules[@b11-ce-8-001]--[@b16-ce-8-001] seemed to be comparable with conventional schedules. Although techniques using hypofractionating schemes have been in use for some time in the treatment of prostate cancer, there is limited experience with such schemes reaching doses ≥ 78 Gy.[@b17-ce-8-001] Our objective was to analyze all published randomized controlled trials that compared the efficacy and side effect profile of hypofractionated versus conventional radiotherapy for prostate cancer.

Materials and methods
=====================

Study selection criteria
------------------------

We included randomized controlled trials with a parallel design that compared the use of hypofractionated (ie, dose per fraction higher than 2.2 Gy) versus conventional radiotherapy (with doses per session ranging between 1.8 and 2.2 Gy). The studies selected included patients with localized prostate cancer without metastases.

Search strategy
---------------

A wide search of the main computerized databases was conducted, including EmBase, LiLACS, Medline, Science Citation Index, the National Cancer Institute Clinical Trials service, and the Clinical Trials Register of Trials Central. In addition, abstracts published in the proceedings of the American Society of Clinical Oncology, American Society of Radiation Oncology (ASTRO), European Society of Medical Oncology, Society of Urologic Oncology, and European Society for Radiotherapy and Oncology were also searched.

For Medline, we used the search strategy methodology for randomized controlled trials[@b18-ce-8-001] recommended by the Cochrane Collaboration.[@b19-ce-8-001] For EmBase, we used adaptations of this same strategy,[@b18-ce-8-001] and for LiLACS, we used the search strategy methodology reported by Castro et al.[@b20-ce-8-001] We performed an additional search in the Science Citation Index database looking for articles that were cited in the included studies. We added specific terms pertinent to this review to the overall search strategy methodology for each database.

The overall search strategy was: \#1 prostatic neoplasms (MeSH Terms), \#2 radiotherapy (MeSH Terms), \#3 hypofractionated (All Fields), and \#4 randomized controlled trial (ptyp). Searches in electronic databases combined the terms \#1 AND \#2 AND \#3 AND \#4.

Critical evaluation of selected studies
---------------------------------------

All the references retrieved by the search strategies had their title and abstract evaluated by two of the researchers. Every reference with the least indication of fulfilling the inclusion criteria was listed as preselected. We retrieved the complete articles of all preselected references. These were analyzed by two different researchers and included or excluded according to the criteria previously described. The excluded trials and the reason of their exclusion are listed in this paper. Data were extracted from all the included trials.

Details regarding the main methodology characteristics empirically linked to bias[@b21-ce-8-001] were extracted, with the methodological validity of each selected trial assessed by two reviewers (TEAB and OC).

Data extraction
---------------

Two independent reviewers extracted the data. The name of the first author and year of publication were used to identify the study. All data were extracted directly from the text or calculated from the available information when necessary. The data from all trials were based on the intention-to-treat principle, so they compared all patients allocated to one treatment with all those allocated to another.

The primary endpoint was freedom from biochemical failure (FFBF). FFBF was defined as the interval from the first day of radiotherapy to the date of biochemical relapse, defined according to the most recent Phoenix definition,[@b22-ce-8-001] ie, the nadir PSA level plus 2 μg/mL, or the ASTRO definition.[@b23-ce-8-001]

Other clinical outcomes were also evaluated, ie, biochemical failure rate, death from tumor rate, and number of patients with adverse events (gastrointestinal and genitourinary, grade ≥ 2). Toxicity was evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer system[@b24-ce-8-001] summarized as: grade 1, minimal side effects not requiring medication; grade 2, symptoms requiring medication; grade 3, requiring minor surgical intervention (transurethral resection, laser coagulation, or blood transfusion); and grade 4, hospitalization and major intervention. Late toxicity was defined as rectal or urinary symptoms occurring or persisting for ≥6 months after the end of radiotherapy.

Analysis and presentation of results
------------------------------------

The data were analyzed using the Review Manager 5.0.24 statistical package (Cochrane Collaboration Software).[@b25-ce-8-001] Dichotomous clinical outcomes are reported as the risk ratio (RR) and survival data as the hazard ratio (HR).[@b26-ce-8-001] The corresponding 95% confidence interval (CI) was calculated, considering *P* values less than 5% (*P* \< 0.05). A statistic for measuring heterogeneity was calculated using the I~2~ method, whereby 25% was considered to be low-level heterogeneity, 25%--50% moderate-level heterogeneity, and \>50% high-level heterogeneity.[@b27-ce-8-001],[@b28-ce-8-001]

To estimate the absolute gains in FFBF, we calculated the meta-analytic survival curves as suggested by Parmar et al.[@b26-ce-8-001] A pooled estimate of the HR was computed by a fixed-effect model according to the inverse variance method.[@b29-ce-8-001] Thus, for effectiveness or side effects, an HR or RR \> 1 favors the standard arm (conventional), whereas an HR or RR \< 1 favors hypofractionated treatment.

If statistical heterogeneity was found in the meta-analysis, we performed an additional analysis using the random-effects model described by DerSimonian and Laird,[@b30-ce-8-001] which provides a more conservative analysis.

To assess the possibility of publication bias, we used the funnel plot test described by Egger et al.[@b31-ce-8-001] When the pooled results were significant, the number of patients needed to treat to cause or to prevent one event was calculated by pooling absolute risk differences in the trials included in this meta-analysis.[@b32-ce-8-001]--[@b34-ce-8-001] For all analysis, a forest plot was generated to display the results.

Results
=======

[Figure 1](#f1-ce-8-001){ref-type="fig"} shows the flow of identification and inclusion of trials, as recommended by the PRISMA (Preferred Reporting Items for Systematic reviews and Meta-Analyses) statement.[@b35-ce-8-001] Overall, 171 references were identified and screened. Twenty studies were selected and retrieved for full-text analysis. Of these, 11 were excluded for various reasons, as described in the additional material presented in [Table 1](#t1-ce-8-001){ref-type="table"}. Details on treatment modality, follow-up, risk group definitions, tumor node metastasis or biochemical failure definitions, and gastrointestinal and genitourinary toxicity in the 11 trials included in the analysis are summarized in [Tables 2](#t2-ce-8-001){ref-type="table"}--[5](#t5-ce-8-001){ref-type="table"}. The total dose of radiation therapy varied among the studies (conventional 64--80 Gy and hypofractionated 52.5--72 Gy) as well as tumor node metastasis and risk ([Table 2](#t2-ce-8-001){ref-type="table"}).

The clinical target volume, in most studies, involved the prostate and seminal vesicles (total or partial). The clinical target volume was the prostate gland alone with a 1.5 cm margin only in two studies.[@b4-ce-8-001],[@b36-ce-8-001]--[@b38-ce-8-001] The most frequent planning target volume was a clinical target volume with a margin of 0.8--1.0 cm ([Table 3](#t3-ce-8-001){ref-type="table"}). Although nine randomized trials on the topic have been included in this analysis, only three studies[@b4-ce-8-001],[@b17-ce-8-001],[@b36-ce-8-001]--[@b39-ce-8-001] reported data on FFBF ([Table 4](#t4-ce-8-001){ref-type="table"}). Overall, the FFBF was similar in patients who received hypofractionated or conventional radiotherapy (fixed effect, HR 1.03, 95% CI 0.88--1.20; *P* = 0.75), with high heterogeneity \[χ^2^ = 15.32, df = 2 (*P* = 0.0005); I[@b2-ce-8-001] = 87%, [Figure 2](#f2-ce-8-001){ref-type="fig"}\]. Two of the studies used the Phoenix definition for FFBF[@b17-ce-8-001],[@b36-ce-8-001]--[@b39-ce-8-001] and one used the ASTRO definition.[@b4-ce-8-001]

The number of patients who had biochemical failure was also similar between the groups (fixed effect, RR 0.99, 95% CI 0.87--1.12; *P* = 0.85) with moderate heterogeneity \[χ^2^ = 7.94, df = 5 (*P* = 0.16); I[@b2-ce-8-001] = 37%, [Figure 3](#f3-ce-8-001){ref-type="fig"}\]. Death from tumor also did not differ between the groups (fixed effect, RR 0.34, 95% CI 0.09--1.23; *P* = 0.10). PSA nadirs ≤ 0.5 ng/mL were reported in two studies[@b17-ce-8-001],[@b39-ce-8-001]--[@b41-ce-8-001] and were similar.

Gastrointestinal and genitourinary acute adverse event data were obtained from six studies[@b4-ce-8-001],[@b8-ce-8-001],[@b17-ce-8-001],[@b39-ce-8-001]--[@b42-ce-8-001],[@b44-ce-8-001]--[@b47-ce-8-001] ([Table 5](#t5-ce-8-001){ref-type="table"}). The incidence of acute adverse gastrointestinal events (grade ≥ 2) was higher in the hypofractionated group (fixed effect, RR 2.02, 95% CI 1.45--2.81; *P* \< 0.0001; number needed to harm = 25). We also found moderate heterogeneity on this analysis \[χ^2^ = 7.47, df = 5 (*P* = 0.19); I[@b2-ce-8-001] = 33%, [Figure 4](#f4-ce-8-001){ref-type="fig"}\]. Two studies[@b4-ce-8-001],[@b36-ce-8-001]--[@b38-ce-8-001] used the two-dimensional technique, and the toxicity rates did not differ between the groups. As planned, we performed a random-effects model analysis, and the results remained favorable for conventional radiotherapy (random effects, RR 1.87, 95% CI 1.20--2.93; *P* = 0.006).

In most studies, acute toxicity was evaluated using the Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer system[@b24-ce-8-001] and late side effects were evaluated using the LENT/SOMA (Late Effects in Normal Tissues Subjective, Objective, Management and Analytic) scale.[@b49-ce-8-001],[@b50-ce-8-001] Acute genitourinary toxicity was similar among the groups (fixed effect, RR 1.19, 95% CI 0.95--1.49; *P* = 0.13), with moderate heterogeneity \[χ^2^ = 5.83, df = 4 (*P* = 0.21); I[@b2-ce-8-001] = 31%, [Figure 4](#f4-ce-8-001){ref-type="fig"}\]. Gastrointestinal or genitourinary late adverse event data were also obtained from six studies[@b4-ce-8-001],[@b8-ce-8-001],[@b17-ce-8-001],[@b39-ce-8-001],[@b43-ce-8-001],[@b45-ce-8-001]--[@b48-ce-8-001] ([Table 5](#t5-ce-8-001){ref-type="table"}). The incidence of all late adverse events was the same for both groups (fixed effect, gastrointestinal, RR 1.17, 95% CI 0.79--1.72; *P* = 0.44 and genitourinary, RR 1.16, 95% CI 0.80--1.68; *P* = 0.44). We found no heterogeneity on this analysis \[gastrointestinal toxicity, χ^2^ = 3.74, df = 5 (*P* = 0.59), I[@b2-ce-8-001] = 0%; and genitourinary toxicity, χ^2^ = 2.73, df = 4 (*P* = 0.60), I[@b2-ce-8-001] = 0%, [Figure 5](#f5-ce-8-001){ref-type="fig"}\].

Subgroup analysis
-----------------

Three studies[@b4-ce-8-001],[@b37-ce-8-001],[@b38-ce-8-001],[@b40-ce-8-001]--[@b42-ce-8-001],[@b51-ce-8-001] did not use hormonal therapy concomitant with radiotherapy. Two of them[@b4-ce-8-001],[@b40-ce-8-001]--[@b42-ce-8-001] reported toxicity data. Acute gastrointestinal toxicity was similar between the groups (fixed effect, RR 1.51, 95% CI 0.78--2.92; *P* = 0.22). Hormonal therapy was permitted in six of the trials,[@b8-ce-8-001],[@b17-ce-8-001],[@b39-ce-8-001],[@b43-ce-8-001]--[@b48-ce-8-001] and acute gastrointestinal toxicity was greater in the HEBRT arm (fixed effect, RR 2.23, 95% CI 1.52--3.27; *P* \< 0.0001), with moderate heterogeneity \[χ^2^ = 6.70, df = 3 (*P* = 0.08); I[@b2-ce-8-001] = 55%\]. When the analysis was performed using the random-effects model, the results remained favorable for CEBRT (random effect, RR 2.04, 95% CI 1.05--3.98; *P* = 0.04).

When we analyzed the subgroup of patients who received only conventional higher doses of radiotherapy (≥78 Gy) versus hypofractionated radiotherapy, only one study[@b17-ce-8-001],[@b39-ce-8-001] with 168 patients reported FFBF and biochemical failure data, making it impossible to perform this meta-analysis. In this particular study, the FFBF was favorable for HEBRT (HR 0.354, 95% CI 0.22--0.58; *P* = 0.004). In a subgroup of patients who received doses from 74 to 77.9 Gy in conventional fractions, the FFBF results were not reported.[@b8-ce-8-001],[@b45-ce-8-001]--[@b48-ce-8-001] The number of patients with biochemical failure was also similar between the groups (fixed effect, RR 0.90, 95% CI 0.54--1.47; *P* = 0.66), with no heterogeneity \[χ^2^ = 0.25, df = 2 (*P* = 0.88); I[@b2-ce-8-001] = 0%\].

Regarding the acute gastrointestinal toxicity in the three studies[@b17-ce-8-001],[@b39-ce-8-001],[@b43-ce-8-001],[@b44-ce-8-001] that used conventional higher doses of radiotherapy (≥78 Gy), the hypofractionated group also showed a higher level of toxicity (fixed effect, RR 2.48, 95% CI 1.61--3.81; *P* \< 0.0001). In this analysis, there was significant heterogeneity \[χ^2^ = 4.51, df = 1 (*P* = 0.03); I[@b2-ce-8-001] = 78%, [Figure 6](#f6-ce-8-001){ref-type="fig"}\]. However, when the analysis was performed using the random-effects model, no significant difference was detected (random effect, RR 2.58, 95% CI 0.94--7.05; *P* = 0.06).

In the subgroup of patients who only used IMRT, the FFBF results were not reported for either CEBRT or HEBRT.[@b8-ce-8-001],[@b45-ce-8-001]--[@b48-ce-8-001] The number of patients with biochemical failure was also similar between the groups (fixed effect, RR 0.93, 95% CI 0.55--1.56; *P* = 0.78) with no heterogeneity \[χ^2^ = 0.06, df = 1 (*P* = 0.80); I[@b2-ce-8-001] = 0%\]. Acute gastrointestinal and genitourinary toxicity was also similar (fixed effect, RR 1.46, 95% CI 0.62--3.43, *P* = 0.38; RR 0.92, 95% CI 0.64--1.31, *P* = 0.64, respectively, [Figure 7](#f7-ce-8-001){ref-type="fig"}), as well as the incidence of late adverse events (fixed effect for gastrointestinal toxicity, RR 1.30, 95% CI 0.73--2.32, *P* = 0.37; fixed effect for genitourinary toxicity, RR 1.16 95% CI 0.75--1.79, *P* = 0.51), with moderate and low heterogeneity, respectively ([Figure 8](#f8-ce-8-001){ref-type="fig"}). In these three studies,[@b8-ce-8-001],[@b45-ce-8-001]--[@b48-ce-8-001] the use of hormonal therapy was permitted.

In the subgroup of patients who received only the three-dimensional technique for both CEBRT and HEBRT,[@b17-ce-8-001],[@b39-ce-8-001]--[@b44-ce-8-001] only Arcangeli et al[@b17-ce-8-001],[@b39-ce-8-001] reported FFBF data. In this particular study, FFBF was favorable for HEBRT (HR 0.354, 95% CI 0.22--0.58; *P* = 0.004). The number of patients with biochemical failure was also similar between the groups (fixed effect, RR 0.53, 95% CI 0.26--1.09; *P* = 0.08), with no heterogeneity \[χ^2^ = 0.04, df = 1 (*P* = 0.84); I[@b2-ce-8-001] = 0%\].

Acute gastrointestinal toxicity was higher in the hypofractionated group (fixed effect, RR 2.37, 95% CI 1.56--3.60; *P* \< 0.0001; number needed to harm = 7), with significant heterogeneity \[χ^2^ = 5.22, df = 2 (*P* = 0.07); I[@b2-ce-8-001] = 62%\]. However, when the analysis was performed using the random-effects model, no significant difference was detected (random effect, RR 2.20, 95% CI 0.96--5.04; *P* = 0.06). Acute genitourinary toxicity was similar (RR 1.13, 95% CI 0.81--1.59; *P* = 0.47), as was the incidence of late adverse events (fixed effect for gastrointestinal toxicity, RR 1.07, 95% CI 0.59--1.95, *P* = 0.82; fixed effect for genitourinary toxicity, RR 1.43, 95% CI 0.47--4.34, *P* = 0.52). Three[@b17-ce-8-001],[@b39-ce-8-001],[@b43-ce-8-001],[@b44-ce-8-001] of the four studies that used the three-dimensional technique permitted use of concomitant hormonal therapy.

According to the funnel plot analysis,[@b31-ce-8-001] the possibility of publication bias was low for all of the outcomes. When the funnel plot shows asymmetry, there is the possibility of publication bias. This method has its limitations, but nonetheless is used widely to assess publication bias.

Discussion
==========

Higher doses of radiotherapy have proven to be more effective for controlling localized prostate cancer. A randomized study with a total of 301 patients with stage T1b to T3 prostate cancer evaluated treatment with 70 Gy doses versus 78 Gy.[@b52-ce-8-001] FFBF was superior for the 78 Gy arm (78%), as compared with the 70 Gy arm (59% *P* = 0.004), and an even greater benefit was seen in patients with initial PSA \> 10 ng/mL (78% versus 39%, *P* = 0.001).[@b52-ce-8-001]

A meta-analysis published later[@b53-ce-8-001] confirmed these data, showing that higher doses of radiotherapy were superior in preventing biochemical failure in patients with low-risk, intermediate-risk, and high-risk prostate cancer, suggesting that this should be offered as the standard of treatment for all patients, regardless of their risk status.

Overall survival is certainly the outcome of greatest importance for any cancer therapy because it incorporates the effect of mortality secondary to cancer, the interventions used, and all other causes. Given the relatively indolent natural history of prostate cancer, it is anticipated that lengthy follow-up is necessary to assess differences in overall survival.[@b54-ce-8-001]

In the present meta-analysis, FFBF was similar between the HEBRT and conventional arms, despite only three studies[@b4-ce-8-001],[@b17-ce-8-001],[@b36-ce-8-001]--[@b39-ce-8-001] reporting FFBF data. However, as noted, only one study[@b17-ce-8-001],[@b39-ce-8-001] used the conventional dose of CEBRT ≥ 78 Gy. The other two[@b4-ce-8-001],[@b36-ce-8-001]--[@b38-ce-8-001] used lower and similar doses, both for the HEBRT and for the conventional arm (Yeoh et al used hypofractionated 55 Gy and conventional 64 Gy; Lukka et al used hypofractionated 52.5 Gy and conventional 66 Gy). In the study that used the higher conventional dose,[@b17-ce-8-001],[@b39-ce-8-001] the FFBF was favorable for HEBRT (*P* = 0.004). Because the median follow-up of this study was small (2.9 years), conclusions concerning optimal disease control are limited.

The biochemical failure rate was generally similar between the radiotherapy regimens. However, when the studies by Lukka et al[@b4-ce-8-001] and Norkus et al,[@b40-ce-8-001]--[@b42-ce-8-001] which used the ASTROS criteria for biochemical failure, were withdrawn, the biochemical failure rate was also favorable for HEBRT.

Although the ASTRO definition is the most widely accepted one for PSA failure, it is associated with limitations.[@b55-ce-8-001],[@b56-ce-8-001] The nadir PSA level ≥ 2 or 3 μg/L definition of biochemical failure was proposed to replace the ASTRO[@b23-ce-8-001] parameters at the Phoenix Consensus Conference,[@b22-ce-8-001] because it has been reported to be more sensitive and specific for the determination of ultimate clinical failure. Duration of hormone therapy varied between 2 and 6 months neoadjuvantly/concomitantly, and only one study used it for 2 years in high-risk patients.[@b45-ce-8-001],[@b46-ce-8-001]

Overall, there were more acute gastrointestinal side effects in the group that used HEBRT. The side effects were even more accentuated when HEBRT was compared with higher doses of CEBRT (≥78 Gy) and when the three-dimensional technique was used with concomitant hormonal therapy. However, no significant difference was detected when the analysis was performed using the random-effects model. Because random-effects models provide a more conservative estimate of the average treatment effect when trials are statistically heterogeneous,[@b30-ce-8-001] we cannot really say whether HEBRT is more toxic when compared with higher doses of CEBRT. A definitive answer will come as more studies are published.

When IMRT was used, the gastrointestinal toxicity (acute and late) did not differ between the groups (HEBRT versus CEBRT), even when use of concomitant hormonal therapy was permitted, but again, the studies that used this technique used lower doses of conventional radiotherapy (74--76 Gy). With this radiotherapy technique, only Pollack et al[@b46-ce-8-001] and Kuban et al[@b48-ce-8-001] reported efficacy (biochemical failure rate) data that were similar over 4--5 years.

An abbreviated course of radiotherapy is more convenient to the patient and possibly less expensive than standard treatment. Some studies are in progress evaluating the use of extreme HEBRT with fractions ≥ 6.1 Gy/day.[@b57-ce-8-001],[@b58-ce-8-001]

The lack of evidence of a long-term therapeutic advantage for hypofractionated compared with conventional radiotherapy dose schedules for prostate cancer is a major obstacle to the adoption of hypofractionated dose schedules in clinical practice.[@b59-ce-8-001] To our knowledge, this was the first meta-analysis on this topic.

Conclusion
==========

Acute gastrointestinal toxicity was higher in the group of patients treated with HEBRT especially when compared with the use of higher doses of CEBRT. When the IMRT technique was used, this difference seemed to decrease. In general, HEBRT was safe with acceptable complication rates.

Overall, in terms of efficacy, the results of HEBRT in localized prostate cancer were not superior to conventional therapy in this meta-analysis. In the study that used the higher conventional dose (≥78 Gy), the FFBF was favorable to HEBRT but the number of patients and the median follow-up of this study was small, so conclusions concerning the best disease control are limited. Future assessments should be conducted to clarify better the real role of hypofractionated radiotherapy in patients with prostate cancer.
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###### 

Characteristics of excluded studies

  Study                             Reason for exclusion
  --------------------------------- -----------------------------------------------
  Martin et al[@b60-ce-8-001]       Not a randomized trial
  Messai et al[@b61-ce-8-001]       Not a randomized trial
  McDonald et al[@b62-ce-8-001]     Not a randomized trial
  Barnett et al[@b63-ce-8-001]      Different comparison
  Syndikus et al[@b64-ce-8-001]     Different comparison
  Viani et al[@b53-ce-8-001]        Meta-analysis of randomized controlled trials
  Whelan et al[@b65-ce-8-001]       Not prostate cancer
  Sundstrom et al[@b66-ce-8-001]    Not prostate cancer
  Siegel et al[@b67-ce-8-001]       Not prostate cancer
  Shahid et al[@b68-ce-8-001]       Not prostate cancer
  Read and Pointon[@b13-ce-8-001]   Not a randomized trial

###### 

Characteristics of studies included for localized prostate cancer

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                 n      TNM or risk group                         RT                    Design                                                                Schedule                                                   ADT   Primary endpoint
  ------------------------------------------------------------------------------------- ------ ----------------------------------------- --------------------- --------------------------------------------------------------------- ---------------------------------------------------------- ----- --------------------------------------------------------
  Yeoh et al[@b36-ce-8-001]--[@b38-ce-8-001]                                            108\   T1--T2N0M0\                               Most 2D method        Hypofractionated versus conventional                                  55 Gy (20 fractions of 2, 7 Gy, 4 wks)\                    No    Late radiation morbidity
                                                                                        109    PSA \< 80                                                                                                                             64 Gy (32 fractions within 6.5 wks)                              

  Arcangeli et al[@b17-ce-8-001],[@b39-ce-8-001]                                        83\    ≥T2c, Gleason ≥ 7 PSA ≥ 20                3D conformal method   Hypofractionated versus conventional                                  62 Gy (20 fractions of 3.1 Gy, 5 wks)\                     Yes   Rates of late complications
                                                                                        85                                                                                                                                           80 Gy (40 fractions of 2 Gy, 8 wks)                              

  Dearnaley et al[@b8-ce-8-001]                                                         153\   T1--T3N0M0 and PSA \< 30 ng/mL            IMRT                  Hypofractionated vs hypofractionated versus conventional              60 Gy (20 fractions of 3 Gy)\                              Yes   Toxicity ≥ grade 2
                                                                                        151\                                                                                                                                         57 Gy (19 fractions of 3 Gy)\                                    
                                                                                        153                                                                                                                                          74 Gy (37 fractions of 2 Gy)                                     

  Norkus et al[@b40-ce-8-001]--[@b42-ce-8-001]                                          47\    T1--3N0M0 and PSA ≤ 10, Gleason \< 7      3D conformal method   Hypofractionated versus conventional                                  57 Gy (13 fractions of 3 Gy plus 4 fractions of 4.5 Gy)\   No    Overall survival, FFBF, biochemical response, toxicity
                                                                                        44                                                                                                                                           74 Gy (37 fractions of 2 Gy)                                     

  Marzi et al[@b43-ce-8-001]                                                            57\    T2c--T4, PSA \> 10 ng/mL, Gleason 7--10   3D conformal method   Hypofractionated versus conventional                                  62 Gy (20 fractions of 3.1 Gy, 5 wks)\                     Yes   Toxicity ≥ grade 2
                                                                                        57                                                                                                                                           80 Gy (40 fractions over 8 wks)                                  

  Strigari et al[@b44-ce-8-001]                                                         80\    localized prostate cancer                 3D conformal method   Hypofractionated versus hypofractionated (IMRT) versus conventional   62 Gy (20 fractions of 3.1 Gy, 4 d/wk)\                    Yes   Toxicity ≥ grade 2
                                                                                        52\                                                                                                                                          56 Gy (16 fractions of 3.5 Gy, 4/wk)\                            
                                                                                        80                                                                                                                                           80 Gy (40 fractions within 8 wks)                                

  Lukka et al[@b4-ce-8-001]                                                             466\   T1--2N0M0 and PSA \< 40                   2D method             Hypofractionated versus conventional                                  52.5 Gy (20 fractions of 2.6 Gy, 28 days)\                 No    Biochemical or clinical failure
                                                                                        470                                                                                                                                          66 Gy (33 fractions over 45 days)                                

  [^\*^](#t2-ce-8-001){ref-type="table"}Pollack et al[@b45-ce-8-001]--[@b47-ce-8-001]   151\   T1--3N0M0 intermediate to high-risk       IMRT                  Hypofractionated versus conventional                                  70.2 Gy (26 fractions of 2.7 Gy)\                          Yes   FFBF
                                                                                        152                                                                                                                                          76 Gy (38 fractions of 2.0 Gy)                                   

  Kuban et al[@b48-ce-8-001]                                                            102\   Low and intermediate-risk                 IMRT                  Hypofractionated versus conventional                                  72 Gy (30 fractions of 2.4 Gy)\                            Yes   Biochemical or clinical failure and toxicity
                                                                                        102                                                                                                                                          75.6 Gy (42 fractions of 1.8 Gy)                                 
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** RT, radiotherapy; wks, weeks; 2D, two-dimensional; 3D, three-dimensional; ADT, androgen deprivation therapy; IMRT, intensity-modulated radiation therapy; FFBF, freedom from biochemical failure; TNM, tumor node metastasis; PSA, prostate-specific androgen.

**Note:** ^\*^Late toxicity data were extracted with the publication Turaka A, et al. 2010.

###### 

Definition of target volumes used in the trials

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                            CTV                                                                             PTV
  ------------------------------------------------ ------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Yeoh et al[@b36-ce-8-001]--[@b38-ce-8-001]       Prostate gland alone with a 1.5 cm margin                                       Prostate + base of seminal vesicles

  Arcangeli et al[@b17-ce-8-001],[@b39-ce-8-001]   Prostate + seminal vesicles                                                     CTV with a margin of 1 cm in each direction, and of 0.6 cm posteriorly

  Dearnaley et al[@b8-ce-8-001]                    Low risk: prostate + base of seminal vesicles + 0.5 cm\                         CTV with a margin of 1 cm in each direction and of 0.5 cm posteriorly
                                                   Moderate risk: prostate + seminal vesicles + 0.5 cm                             

  Norkus et al[@b40-ce-8-001]--[@b42-ce-8-001]     Prostate + base of seminal vesicles                                             CTV plus a uniform expansion of 0.8--1 cm in all directions

  Marzi et al[@b43-ce-8-001]                       Prostate + seminal vesicles                                                     CTV with a margin of 1 cm in each direction and of 0.6 cm posteriorly

  Strigari et al[@b44-ce-8-001]                    Prostate + seminal vesicles(except stage T1−T2 = prostate only)                 CTV plus a uniform expansion of 0.8 cm in all directions

  Lukka et al[@b4-ce-8-001]                        Prostate gland alone with a 1.5 cm margin                                       Margin of 1.5 cm in each direction and of 1.0 cm posteriorly

  Pollack et al[@b45-ce-8-001]--[@b47-ce-8-001]    Intermediate risk: prostate + proximal seminal vesicles (approximately 9 mm)\   Conventional: CTV with a margin of 0.8 cm in each direction and of 0.5 cm posteriorly Hypofractionated: CTV with a margin of 0.7 cm in each direction and of 0.3 cm posteriorly
                                                   High-risk: prostate + 50% of the seminal vesicles and pelvic lymph nodes        

  Kuban et al[@b48-ce-8-001]                       NR                                                                              NR
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Abbreviations:** CTV, clinical target volume; PTV, planning target volume; NR, not reported.

###### 

Efficacy analysis in the trials included in the meta-analysis

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                                                Design                     n                     BF                                              FFBF                                              nPSA ≤0.5 ng/mL   Death from tumor   Median follow-up
  ------------------------------------------------------------------------------------ -------------------------- --------------------- ----------------------------------------------- ------------------------------------------------- ----------------- ------------------ ------------------
  Yeoh et al[@b36-ce-8-001]--[@b38-ce-8-001]                                           Hypofractionated           108                   36 (33.3%)                                      57 (53%)                                          NR                2 (1,85%)          7.5 years

  Conventional                                                                         109                        49 (44.9%)\           37 (34%)\                                                                                         4 (3.66%)                            
                                                                                                                  *P* \< 0.05           *P* \< 0.05;\                                                                                                                          
                                                                                                                                        HR 0.65\                                                                                                                               
                                                                                                                                        95% CI (0.42--0.99)                                                                                                                    

  Arcangeli et al[@b17-ce-8-001],[@b39-ce-8-001]                                       Hypofractionated           83                    8 (10%)                                         68 (82%)                                          83 (100%)         0 (0%)             2.9 years

  Conventional                                                                         85                         16 (19%) *P* = 0.14   51 (60%)\                                       80 (94%) *P* = NS                                 1 (1%)\                              
                                                                                                                                        *P* = 0.004\                                                                                      *P* = 0.99                           
                                                                                                                                        HR 0.354\                                                                                                                              
                                                                                                                                        95% CI (0.22--0.58)                                                                                                                    

  Dearnaley et al[@b8-ce-8-001]                                                        Hypofractionated (60 Gy)   153                   NR                                              NR                                                NR                NR                 4.2 years

  Hypofractionated (57 Gy)                                                             151                                                                                                                                                                                     

  Conventional                                                                         153                                                                                                                                                                                     

  [^\*^](#t4-ce-8-001){ref-type="table"}Norkus et al[@b40-ce-8-001]--[@b42-ce-8-001]   Hypofractionated           47                    2 (4.25%)                                       NR                                                8 (18.2%)         0 (0%)             1 year

  Conventional                                                                         44                         3 (6.81%)                                                             10 (25%)\                                         0 (0%)                               
                                                                                                                                                                                        *P* = 0.62                                                                             

  Marzi et al[@b43-ce-8-001]                                                           Hypofractionated           57                    NR                                              NR                                                NR                NR                 2.5 years

  Conventional                                                                         57                                                                                                                                                                                      

  Strigari et al[@b44-ce-8-001]                                                        Hypofractionated (62 Gy)   80                    NR                                              NR                                                NR                NR                 \<2 months

  Hypofractionated (56 Gy) IMRT                                                        52                                                                                                                                                                                      

  Conventional                                                                         80                                                                                                                                                                                      

  [^\*^](#t4-ce-8-001){ref-type="table"}Lukka et al[@b4-ce-8-001]                      Hypofractionated           466                   217 (47%)                                       [^\*\*^](#t4-ce-8-001){ref-type="table"}HR 1.18   NR                0 (0%)             5.7 years

  Conventional                                                                         470                        199 (42%)             (95% CI, 0.99--1.41) in favor of conventional                                                     3 (1.0%)                             

  Pollack et al[@b45-ce-8-001]--[@b47-ce-8-001]                                        Hypofractionated           151                   20 (13.9%)                                      NR                                                NR                NR                 5 years

  Conventional                                                                         152                        21 (14.4%)                                                                                                                                                   

  Kuban et al[@b48-ce-8-001]                                                           Hypofractionated           102                   4 (3.92%)                                       NR                                                NR                0 (0%)             4.6 years

  Conventional                                                                         102                        5 (4.9%)                                                                                                                0 (0%)                               
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Notes:** ^\*^FFBF was defined as American Society for Therapeutic Radiology and Oncology Consensus,[@b23-ce-8-001] ie, three consecutive increases in PSA is a reasonable definition of biochemical failure after radiation therapy. ^\*\*^Freedom from biochemical or clinical failure.

**Abbreviations:** nPSA, nadir prostate specific antigen; FFBF, freedom from biochemical failure; BF, biochemical failure; NR, not reported; NS, not significant.

###### 

Gastrointestinal and genitourinary toxicity in the trials included in the meta-analysis

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                            Design                     n                                                    Toxicity gastrointestinal (grade ≥ 2)                Toxicity genitourinary (grade ≥ 2)                                                                        
  ------------------------------------------------ -------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ---------------------------------------------------- ------------
  Yeoh et al[@b36-ce-8-001]--[@b38-ce-8-001]       Hypofractionated           108                                                  NR                                                   NR                                                   NR                                                   NR

  Conventional                                     109                        *P* = NS                                             *P* = NS                                             *P* = NS                                             *P* = NS                                             

  Arcangeli et al[@b17-ce-8-001],[@b39-ce-8-001]   Hypofractionated           83                                                   29 (35%)                                             12 (14%)                                             39 (47%)                                             7 (8%)

  Conventional                                     85                         18 (21%)                                             10 (12%)                                             34 (40%)                                             5 (6%)                                               

                                                                              *P* = 0.07                                           *P* = 0.55                                           *P* = 0.45                                           *P* = 0.092                                          

  Dearnaley et al[@b8-ce-8-001]                    Hypofractionated (60 Gy)   153                                                  3 (2.3%)                                             5 (3.6%)                                             10 (7.6%)                                            3 (2.2%)

  Hypofractionated (57 Gy)                         151                        1 (0.8%)                                             2 (1.4%)                                             9 (7.0%)                                             0 (0%)                                               

  Conventional (74 Gy)                             153                        3 (2.3%)                                             6 (4.3%)                                             9 (7.0%)                                             3 (2.2%)                                             

  Norkus et al[@b40-ce-8-001]--[@b42-ce-8-001]     Hypofractionated           47                                                   [^\*\*^](#t5-ce-8-001){ref-type="table"}2 (18.18%)   NR                                                   [^\*\*^](#t5-ce-8-001){ref-type="table"}2 (18.18%)   NR

  Conventional                                     44                         [^\*\*^](#t5-ce-8-001){ref-type="table"}2 (18.18%)                                                        [^\*\*^](#t5-ce-8-001){ref-type="table"}3 (27.27%)                                                        

  Marzi et al[@b43-ce-8-001]                       Hypofractionated           57                                                   NR                                                   7 (12.3%)                                            NR                                                   NR

  Conventional                                     57                                                                              8 (14.0%)\                                                                                                                                                     
                                                                                                                                   *P* = 0.688                                                                                                                                                    

  Strigari et al[@b44-ce-8-001]                    Hypofractionated (62 Gy)   80                                                   20 (25%)                                             NR                                                   NR                                                   NR

  Hypofractionated (56 Gy)                         52                         22 (42.5%)                                                                                                                                                                                                          

  Conventional                                     80                         6 (8.0%)\                                                                                                                                                                                                           
                                                                              *P* \< 0.0001                                                                                                                                                                                                       

  Lukka et al[@b4-ce-8-001]                        Hypofractionated           466                                                  [^\*^](#t5-ce-8-001){ref-type="table"}19 (4.1%)      6 (1.3%)                                             40 (8.6%)                                            9 (1.9%)

  Conventional                                     470                        12 (2.6%)                                            6 (1.3%)                                             23 (4.9%)                                            9 (1.9%)                                             

  Pollack et al[@b45-ce-8-001],[@b47-ce-8-001]     Hypofractionated           151                                                  [^\*\*^](#t5-ce-8-001){ref-type="table"}9 (18%)      9 (5.9%)                                             [^\*\*^](#t5-ce-8-001){ref-type="table"}24 (48%)     21 (13.8%)

  Conventional                                     152                        [^\*\*^](#t5-ce-8-001){ref-type="table"}4 (8%)       6 (4.1%)                                             [^\*\*^](#t5-ce-8-001){ref-type="table"}28 (56%)     13 (8.9%)                                            

                                                                              *P* = NS                                             *P* = 0.754                                          *P* = NS                                             *P* = 0.041                                          

  Kuban et al[@b48-ce-8-001]                       Hypofractionated           102                                                  NR                                                   11 (10%)                                             NR                                                   15 (19%)

  Conventional                                     102                                                                             5 (4.9%)\                                                                                                 16 (19%) *P* = NS                                    
                                                                                                                                   *P* = NS                                                                                                                                                       
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

**Note:** ^\*^Toxicity grade ≥ III; ^\*\*^toxicities extracted from the first publication.

**Abbreviations:** NR, not reported; NS, not significant.
